HBV Treatment
EASL 2013: Truvada Works Best for Immune-Tolerant Hepatitis B Patients -- But Do They Need Treatment?
- Details
- Category: HBV Treatment
- Published on Monday, 29 April 2013 00:00
- Written by Liz Highleyman
A combination of tenofovir and emtricitabine (the drugs in Truvada) suppressed hepatitis B virus (HBV) replication more than tenofovir alone over 4 years for people with inactive or immune-tolerant disease, researchers reported at the EASL International Liver Congress (EASL 2013) this week in Amsterdam. The benefits of treatment at this early stage, however, remain uncertain.
Coverage of the 2013 EASL International Liver Congress
- Details
- Category: HBV Treatment
- Published on Saturday, 27 April 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) in Amsterdam, April 24-28, 2013.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, and prevention and treatment of hepatocellular carcinoma.
4/27/13
EASL 2013: International Liver Congress Kicks Off with Hep C New Drug Highlights
- Details
- Category: HBV Treatment
- Published on Wednesday, 24 April 2013 00:00
- Written by Liz Highleyman
The EASL International Liver Congress is now underway at the Amsterdam RAI congress center. At a Wednesday press conference, EASL officials gave a preview of some of the hepatitis C treatment highlights -- both augmentation of interferon-based therapy and interferon-free regimens -- to be presented at the meeting, which runs through Sunday.
EASL 2013: Long-term Tenofovir Reduces Liver Cancer Risk in People with Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Published on Friday, 26 April 2013 00:00
- Written by Liz Highleyman
Long-term treatment with tenofovir (Viread) lowered the risk of developing hepatocellular carcinoma among people with chronic hepatitis B, with a notable divergence from expected rates after about 5 years, according to a report presented at the at the EASL International Liver Congress (EASL 2013) this week in Amsterdam.
Heavy Alcohol Use Increases Liver Cancer Risk in Hepatitis B Patients with Cirrhosis
- Details
- Category: HBV Treatment
- Published on Wednesday, 24 April 2013 00:00
- Written by Liz Highleyman
Heavy drinking can add to the already elevated likelihood that people with liver cirrhosis related to hepatitis B virus (HBV) infection will develop hepatocellular carcinoma (HCC), according to a study published in the April 2013 Journal of Hepatology.
More Articles...
- EASL International Liver Congress Starts this Week in Amsterdam
- CROI 2013: Dually Active Antiretroviral Therapy Protects Against Primary Hepatitis B Infection
- Antioxidant N-acetylcysteine Improves Survival of Transplanted Liver
- Most Hepatitis B Patients Who Respond to Tenofovir Show Improved Liver Health at 5 Years
Web Design and Development by